We are committed to providing doctors with more information to facilitate more personalized decision-making for each patient.
(PRWEB) April 11, 2016
Proove Biosciences, Inc., the commercial and research leader in personalized pain medicine, is excited to announce the launch of its expanded Proove Drug Metabolism™ Genetic Profile. The drug metabolism profile is the most comprehensive pharmacogenetics test on the market—and it now includes a drug-class summary of cardiology medications. Designed for patients undergoing—or for patients who are candidates for medication management—the profile analyzes enzymes that metabolize a majority of medications physicians currently prescribe. The genetic profile allows doctors to better predict if drug metabolism variations may contribute to side effects or influence dosing changes for prescription and over-the-counter medications.
“We are committed to providing doctors with more information to facilitate more personalized decision-making for each patient,” said Svetlana Kantorovich, Ph.D., Director of Scientific and Clinical Affairs. “With the release of the cardiology portion of our drug metabolism profile, we are able to help physicians receive more detailed information on commonly used statins, anti-coagulants, and other important heart medications. As orthopedic surgeons reintroduce anti-coagulants after surgery or pain physicians evaluate chronic pain patients with co-occurring heart disease, this updated report will provide even more value.”
The Proove Drug Metabolism™ Genetic Profile assesses how a patient metabolizes each medication based on genetic factors. “At Proove, we are focused on the number one reason patients seek treatment from their primary care doctor—pain. Since many of these patients also have heart disease, this improvement to the Proove Drug Metabolism™ Genetic Profile delivers even more value to our physician, patient, and payer partners,” said Brian Meshkin, CEO at Proove Biosciences.
The expanded profile allows doctors to get an objective evaluation of pain, psychiatric, and cardiology medications on a single test. “In 2015 alone, we enrolled over 34,000 patients in multi-center IRB-approved clinical studies across leading institutions like USC and Hoag, as well as large community clinics. These data inform our product improvements and we are excited to make it easier for doctors to treat patients with greater precision,” said Dr. Kantorovich. The updated Proove Drug Metabolism™ Genetic Profile is available as of April 11, 2016.
About Proove Biosciences
Our mission is to change the future of medicine. Proove represents the proof to improve healthcare decisions. We seek to realize a future when clinicians look back and wonder how they could have ever prescribed medications without knowing how a patient would respond. Physicians use Proove Biosciences testing to improve outcomes—both safety and efficacy of medical treatment. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).